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CD271 is a molecular switch with 
divergent roles in melanoma and 
melanocyte development
Fabian V. Filipp  1,2,3, Chen Li4,5 & Alexander D. Boiko4,5
Dysregulation of signaling networks controlling self-renewal and migration of developmental cell 
lineages is closely linked to the proliferative and invasive properties of tumors. Identification of such 
signaling pathways and their critical regulators is vital for successful design of effective targeted 
therapies against neoplastic tissue growth. The neurotrophin receptor (CD271/NGFR/p75NTR) is a 
key regulator of the melanocytic cell lineage through its ability to mediate cell growth, survival, and 
differentiation. Using clinical melanoma samples, normal melanocytes and global gene expression 
profiling we have investigated the role of CD271 in rewiring signal transduction networks of melanoma 
cells during neoplastic transformation. Our analysis demonstrates that depending on the cell fate 
of tumor initiation vs normal development, elevated levels of CD271 can serve as a switch between 
proliferation/survival and differentiation/cell death. Two divergent arms of neurotrophin signaling hold 
the balance between positive regulators of tumor growth controlled by E2F, MYC, SREBP1 and AKT3 
pathways on the one hand, and differentiation, senescence, and apoptosis controlled by TRAF6/IRAK-
dependent activation of AP1 and TP53 mediated processes on the other hand. A molecular network 
map revealed in this study uncovers CD271 as a context-specific molecular switch between normal 
development and malignant transformation.
Melanoma represents one of the most aggressive types of cancer due to its high proliferative and metastatic poten-
tial1. Multiple studies have indicated that melanoma progression partially recapitulates a developmental program 
of normal melanocytic lineage, by hijacking signaling pathways active in stem/progenitor cell populations during 
normal development2–5. At the embryonic stages, melanocytes and their precursors, melanoblasts, are derived 
from a multipotent stem cell population, neural crest6. This highly proliferative and migratory cell population can 
be defined by the expression of the nerve growth factor receptor, CD271(NGFR/p75NTR)7,8.
Our group and others have previously demonstrated that within human melanomas, cells expressing neu-
ral crest stem cell marker, CD271, represent the most aggressive tumor-and metastasis-initiating cell popula-
tion9–11. Using surgically removed human tumors combined with an advanced techniques of cell isolation these 
studies demonstrated that CD271+ melanoma cells have increased tumor-initiating capacity, self-renew and 
can serially transplant the disease in-vivo recapitulating original patient tumor morphology and heterogeneity 
giving rise to CD271+ and CD271− cells9,10. Despite an ongoing debate whether frequency of CD271+ human 
tumor-initiating cells is over- or under-estimated as a result of modifications in the mouse xenotransplantation 
protocols, including the use of high-protein matrigel12,13, their true physiological frequency in human patients 
cannot be determined due to the fact that it would require isogenic transplantations, which are impossible to 
perform. Nonetheless, the clinical value of melanoma-initiating cells, namely characterization of their phenotypic 
and molecular properties bears significant impact on the development of targeted anti-melanoma therapeutic 
regimens14–21.
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Since their identification, melanoma-initiating cells and high levels of CD271 expression have been associated 
with metastatic progression, enhanced survival, resistance to the chemotherapeutic agents, including MAPK 
inhibitors, and evasion of the immune system, through de-differentiation and downregulation of T-Cell activat-
ing antigens9,10,14–16,18–20,22–25. Antibody-mediated targeting of CD271+ melanoma cells has recently been shown 
to synergize with the activation of an innate immune response via CD47 blockade and dramatically reduce tumor 
growth, as well as, the lymph node and distant organ metastases in mice xenotransplanted with patient derived 
melanomas9. Downregulation of CD271 using shRNA mediated gene knockdown abolishes tumorigenic growth 
of melanoma cells in-vivo, reduces their migratory properties and predisposes them to the DNA damaging, apop-
tosis inducing, stimuli11. Tumorigenic stem cell properties of CD271 signaling had also been demonstrated for 
head and neck cancers, where its knockdown led to the defects in cell proliferation and tumor regression26.
Neurotrophins (nerve growth factors) mediate growth, death, survival, and differentiation of the cells when 
they bind to their cognate target receptors27. They are recognized by two classes of receptors, CD271 and recep-
tor tyrosine kinase (RTK/TRK) members, both of which belong to the large tumor necrosis factor receptor 
superfamily28. These receptors transmit intracellular signals through several canonical pathways, including the 
mitogen activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/AKT signaling pathways29. 
Conversely, CD271 has the ability to facilitate a broad functional spectrum including opposing functions of cell 
death and survival in its capacity as signaling receptor for stem cell or inhibitory components30–32. Thus, the phys-
iological consequences of CD271 depend on the cellular context of its signaling33.
Unraveling heterogeneity of CD271 signaling to discover new subpopulations of cells within the tumor has 
been fundamental to many advances in cancer biology, including identification of tumor-initiating subsets and 
cells resisting immune-therapeutic regimens9,18–20. In this systems biology study, using clinical melanoma sam-
ples, fluorescent-activated cell sorting (FACS) in combination with global transcriptome profiling, we report 
distinct signaling pathways connected to CD271 expression in melanoma and melanocytes. CD271+ cells derived 
from human melanoma patients in comparison to CD271− counterparts and CD271+ cells derived from nor-
mal melanocytic lineages elucidate a contrasting network response during normal development and malignant 
transformation.
Results
Generation of patient-derived CD271+ vs CD271− transcriptome profiles. We previously used 
clinical melanoma tumor specimens to classify CD271+ cell populations as tumor-initiating9. Isolation of these 
cells to the highest degree of purity provided unique opportunity to compare transcriptional profiles across mul-
tiple patients, between CD271+ and CD271− populations. We utilized flow cytometry in combination with line-
age- and CD271-specific monoclonal antibodies to purify distinct CD271+ and CD271− tumor cell subsets from 
surgically removed, human tumor tissue specimens, described in detail9 (Fig. 1A). In addition, we used the same 
approach to purify CD271+ and CD271− cell population from epidermal melanocytes separately isolated from 
healthy human skin tissue. All CD271+ and CD271− cell populations were then subjected to RNA extraction, 
transcriptomic profiling, and systems biology analysis.
Clustering based on Pearson correlation, principal component analysis (PCA), and heatmap visualization pro-
vided a global overview of patient-derived CD271+ vs CD271− transcriptome profiles of melanomas and melano-
cytes. In the column dimension of the clustering, melanomas and melanocytes specimens were segregated based 
on CD271 status (Fig. 1B). The row dimension provided first insight into processes that were differently expressed 
in melanoma-initiating CD271+ cells vs CD271− cells from matching tumors that were unable to initiate tumor 
growth in-vivo or had a much lower efficiency9. In addition, separate clusters of CD271+ and CD271− melano-
cytes provided second dimension of comparison revealing specific signaling pathways unique to tumor-initiating 
CD271+ melanoma cells (Fig. 1B). The first branches of the row tree included cell cycle progression, pathways 
of neurotrophin and NOTCH signaling, cell survival and immune responses. Gene members of such pathways 
were in general higher expressed in the CD271+ melanoma-initiating cells compared to CD271− melanoma cells 
and CD271+ melanocytes. The next branches of the row tree included cell-cell contacts, tissue homeostasis, and 
TP53 mediated singing networks of cell cycle arrest and apoptosis. Importantly, these pathways, typical for tissue 
differentiation, were downregulated in CD271+ melanoma cells, but were upregulated in CD271− counterparts 
and had the strongest expression in the CD271+ normal melanocytes (Fig. 1B).
The patient-derived tumor specimens in this study represented a considerable amount of heterogeneity 
including different site of diagnosis, and the status of BRAF activation (Supplementary Table 1). Nonetheless, 
PCA based on the cell surface CD271 status, separated melanoma and melanocyte specimens into two clusters 
with 50% data representation in the first two principal components (PC1 = 28% and PC2 = 22%) (Fig. 1B). The 
principal components showed that the average perturbation of the CD271+ melanoma-initiating cells is in the 
opposite direction and of greater magnitude compared to the CD271+ melanocytes. CD271 expression had a 
strong impact on melanoma transcriptomes yet unsupervised clustering and PCA showed distinct effects in mel-
anocytes (Fig. 1B).
Next, we used qRT-PCR and gene-specific primers (Supplementary Table 2) and FACS sorted CD271+/
CD271− melanoma cell populations, as well as, CD271+/CD271− normal melanocytes, to confirm specific clus-
ters of CD271 mediated gene expression. We validated top hits of representative genes involved in self-renewal, 
cell survival, and epigenetic rewiring. As a positive control we also measured gene expression of CD271 in the 
same cell populations. Thus, AKT3, HDAC9, TCF12, and LEF1 were differentially expressed in the melanoma 
specimens, tracking with CD271 enrichment (Fig. 2). In contrast, melanocytes reversed transcription levels of 
such markers, despite elevated levels of CD271.
Taken together, the CD271 effect between CD271+ vs CD271− cells created distinct clusters of transcripts that 
were functionally connected by cellular pathways. Nevertheless, given an underlying cellular fate of oncogenic 
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program vs normal development, an overarching theme of opposing signaling branches separated CD271+ mel-
anoma and melanocyte enriched cells with transcriptional responses in opposite directions.
CD271 positively regulates gene networks associated with melanoma progression. Our next 
step was to delineate cellular pathways that were uniquely associated with CD271+ in comparison to CD271− 
in melanoma and melanocyte cells. CD271 expression had a strong impact on melanoma transcriptomes yet 
unsupervised clustering and PCA showed distinct, opposite effects in CD271− melanoma cells and melanocytes 
(Figs 1–3). CD271+ melanoma-initiating cells showed significant overrepresentation of proliferative pathways 
in comparison to CD271− matching tumor cells, as well as, CD271+ melanocyte transcriptomes (Fig. 3). Key 
pathways of cell cycle processes, E2F effector target genes, and DNA replication were significantly enriched 
with p values below 0.05 and q values below 0.25. Intriguingly, the same pathways that are upregulated in mel-
anoma in the presence of CD271 are downregulated in CD271+ melanocytes (Fig. 3). Transcripts associated 
with representatives of cell cycle regulators including cyclins (CCNA2, CCNB2, CCNE1), cyclin-dependent 
protein kinases (CDC2, CDC20), centromere proteins (CENPE, CENPF), retinoblastoma binding proteins 
(RBBP6), were all enriched in CD271+ melanoma-initiating cells but downregulated in CD271− melanoma cells 
and CD271+ melanocytes. As a result, target genes carrying E2F sequence motifs in their promoter sites are 
enriched in CD271+ melanoma cell population (Fig. 4). Moreover, differential analysis of transcriptomic data 
revealed that gene nodes associated with non-canonical WNT or NOTCH signaling were significantly activated 
in CD271+ melanoma-initiating cells, but they were absent from or not activated in CD271− melanoma cells and 
terminally differentiated melanocytes (Figs 1–3, Table 1). Specifically, we revealed strong activation of the basic 
helix-loop-helix transcriptional complex of TCF and LEF effector genes. In addition, selected members of NFKB 
and NOTCH signaling pathways (IKBKB, NOTCH2, HES1, PRKCA) were strongly overrepresented in CD271+ 
melanoma-initiating cells (Table 1).
Figure 1. CD271 expression has a strong impact on melanoma transcriptome and has distinct effect in melanocytes. 
(A) Experimental design of patient-derived transcriptomic profiles of CD271+ and CD271− melanoma cells in 
comparison with profiles of healthy donor melanocytes. All cell populations were sorted by flow cytometry and 
subjected to transcriptomic profiling. (B) Heat map of gene expression profiles and indication of CD271 status in 
tumor cells (pink and purple) vs normal melanocytes (grey). Selfrenewal, cell cycle and cell survival pathways are 
significantly overrepresented with p values below 0.05 in CD271+ melanoma-initiating cells vs CD271− cells and 
normal melanocytes. Principal component analysis (PCA) reveals separation of expression profiles.
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Overall, CD271+ melanoma cells were associated with a highly proliferative and mitotic state as compared 
to CD271− cells from the matching tumors. In contrast, CD271+ cells derived from normal melanocytes were 
enriched for the pathways and processes driving differentiation (Figs 3, 4; Table 1).
Impact of CD271 on cell survival and DNA repair processes. Gene expression analysis iden-
tified activation of AKT3, but not AKT1 or AKT2, as a major cell survival node upregulated in CD271+ 
melanoma-initiating cells. Using system pathway profiling analysis we reveal the molecular network model 
(Fig. 5), which illustrates how different neurotrophin receptor-dependent adaptor proteins, including GRB2, 
SHC, and GAB1 connect activation of CD271 to the upregulation of AKT3 in CD271+ melanoma-initiating 
cells. In addition to GAB1 and SHC-dependent PI3K signaling, tyrosine or serine/threonine kinases have been 
shown to activate AKT directly, in response to growth factors, inflammation or DNA damage. These can function 
even when PI3K activity is inhibited. AKT can also be activated in response to increases in cellular Ca2+ concen-
tration, via Ca2+/Calmodulin-dependent protein kinase II (CAMKII). All of the above molecular components 
were transcriptionally upregulated in CD271+ melanoma-initiating cells, while being absent or downregulated in 
CD271− counterparts and CD271+ melanocytes (Table 1, Figs 1B, 5).
The differential analysis filtered for processes driven by CD271 in tumor-initiating cells also revealed enrich-
ment for the genes participating in nucleotide excision repair (NER, including damage recognition and repair 
factor XPC, DNA repair associated BRCA2, UBE2I, COPS7A, POLD3, USP45, RFC5) (Fig. 3C). Activation of 
NER pathways bears special significance to the tumor-initiating cells with stem-like properties, which have to 
limit the extent of genomic damage in order to survive for prolonged periods of time.
Figure 2. Transcriptional validation of differentially expressed genes by qRT-PCR based on CD271 status 
and normalization against 18 s RNA using the ΔCT method. The fold change for a transcript of interest 
was determined by taking the ratio of normalized gene expression between CD271+ and CD271− cell 
populations for each patient sample. In brief, differential gene expression was determined by calculating 
the fold change of any gene of interest (GOI) = 2−ΔΔCT, where ΔCT(GOI) = (CT(GOI) − CT(18 s) and 
ΔΔCT(GOI) = ΔCT(GOI-condition A) − ΔCT(GOI condition B) with CD271+ and CD271− for condition A 
and B, respectively.
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Differential impact of CD271 on melanocyte development as compared to melanomagenesis. 
Developmental pathways that are important to direct differentiation within the melanocytic lineage were 
enriched in CD271+ melanocytes but are inhibited in CD271+ melanoma-initiating cells. Thus, signal transduc-
tion networks associated with skin development, metabolic hormone processes, cell adhesion, and ion channel 
activity are significantly enriched in CD271+ melanocytes with p values below 0.05 and q values below 0.25. 
The same pathways that are upregulated in melanocytes and important maintenance and differentiated tissue 
are downregulated in melanoma in the presence of CD271 (Figs 3, 4). In addition, the neurotrophin signaling 
showed distinct rewiring, where CD271 expression correlated with switched activity of JNK and TRAF6 pathways 
in melanoma and melanocytes (Fig. 5). Interestingly, our analysis established that CD271+ melanoma cells had 
similar gene expression profiles to TRAF6 knockout cell lines34. Neurons with TRAF6 associated with CD271 
operate JNK-dependent apoptosis to guide cerebellar development35. In the same fashion, CD271 signaling in 
melanoma does not rely on TRAF6, which is significantly downregulated (Fig. 5). In contrast, when the same 
CD271 receptor is enriched and active in melanocytic lineages during physiologic conditions, it stimulates termi-
nal differentiation leading to non-proliferative states and expression of pigment associated melanocytic markers 
(including keratins KRT1, KRT9, KRT16, KRT25, KRT71, collagen type I alpha 2 chain COL1A2, differentiation 
Figure 3. Stimulation of the cell cycle, DNA repair and cell survival in CD271+ melanoma cells, in contrast to 
emphasis on differentiation processes in CD271− cells and normal melanocytes. The ratio of CD271+/CD271− 
transcriptomes reveals enrichment of CD271-associated pathways. Directional, normalized enrichment scores 
are color-coded (positive in yellow, negative in blue) and functionally grouped by cell type for melanoma and 
melanocytes for (A) cell cycle processes, (B) differentiation processes, and (C) nucleotide excision repair (NER).
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transcription factors FOXE1, HOXC13, SRF, FOSL2, growth factors TGFB2, FGF10, SOS1, integrins ITGA2, 
ITGB4, CD109, and WNT16) (Table 1).
Discussion
In the present study, we demonstrate that depending on the state of the tissue homeostasis elevated levels of the 
neurotrophin receptor, CD271, can serve as a cell proliferative/survival switch for melanoma-initiating cells or 
as a differentiation switch for developing melanocytes. In melanoma and melanocytes, CD271 was significantly 
associated with similar networks yet opposing roles. Comprehensive analysis of highly purified CD271+ and 
CD271− cell populations from malignant melanomas and normal melanocytes revealed two divergent arms of 
neurotrophin signaling, which balance between proliferative cell cycle signals, survival and epigenetic rewiring 
on one hand, and apoptosis, senescence, and developmental triggers on the other hand. Thus, significant pathway 
enrichment connected CD271 in melanoma with gene targets of E2F, MYC, SREBP1, and PI3-kinase signal-
ing (Figs 1, 3, 4, Table 1). At the same time, differentiation and cell death triggers including TRAF6-dependent 
JUN-kinase activation of the AP1 complex and TP53 was suppressed (Fig. 5).
The systems biology analysis performed in this study revealed that upregulation of self-renewing genes in 
CD271+ melanoma cells occurs in response to the activation of E2F, MYC, and SREBF1 promoter-containing 
elements. Target genes containing these response elements in their promoters (summarized in Table 1) are known 
to hold critical roles in cell cycle progression and DNA replication, which together are required efficient cell 
Figure 4. Overrepresentation of the E2F transcription factor responsive pathways and cell cycle processes in 
CD271+ melanoma cells in contrast to differentiation processes in CD271− cells and normal melanocytes. Gene 
set enrichment analysis with statistical scores for (A) melanoma and (B) melanocytes.
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Pathway
Melanoma Melanocytes
NES p value q value NES p value q value
E2F targets 3.18 0.00E + 00 0.00E + 00 −2.39 0.00E + 00 8.65E − 03
MYC targets 1.86 4.01E − 03 4.50E − 02 −1.70 3.19E − 02 2.28E − 01
nucleotide excision repair 2.31 1.91E − 03 1.88E − 02 −1.99 6.07E − 03 8.04E − 02
dna replication 2.87 0.00E + 00 0.00E + 00 −2.29 0.00E + 00 1.53E − 01
mitotic m m g1 phases 2.69 0.00E + 00 8.50E − 04 −2.24 0.00E + 00 7.42E − 02
global genomic ner gg ner 2.32 4.12E − 03 1.72E − 02 −2.05 1.00E − 02 1.44E − 01
class i mhc mediated antigen processing presentation 2.17 4.32E − 03 3.70E − 02 −1.90 1.01E − 02 2.37E − 01
metabolism of rna 2.14 1.93E − 03 4.03E − 02 −2.00 8.03E − 03 1.73E − 01
mitotic prometaphase 2.09 0.00E + 00 5.62E − 02 −1.89 1.36E − 02 2.38E − 01
antigen processing ubiquitination proteasome degradation 2.02 2.22E − 03 7.67E − 02 −1.86 1.22E − 02 2.11E − 01
metabolism of mrna 1.91 6.56E − 03 9.71E − 02 −2.21 1.95E − 03 6.75E − 02
formation of incision complex in gg ner 1.88 1.24E − 02 9.93E − 02 −1.98 5.93E − 03 1.78E − 01
deadenylation dependent mrna decay 1.69 2.07E − 02 1.65E − 01 −1.89 3.95E − 03 2.20E − 01
CENPE 2.58 2.07E − 03 3.62E − 03 −1.73 2.08E − 02 2.25E − 01
CDC2 2.46 2.07E − 03 4.39E − 03 −2.09 7.81E − 03 8.91E − 02
CCNB2 2.35 0.00E + 00 5.86E − 03 −1.71 2.12E − 02 2.30E − 01
CCNA2 2.32 2.11E − 03 6.96E − 03 −2.32 0.00E + 00 5.05E − 02
SMC2L1 2.31 0.00E + 00 6.86E − 03 −1.77 1.62E − 02 2.00E − 01
HMMR 2.31 2.00E − 03 6.55E − 03 −1.95 6.13E − 03 1.21E − 01
RRM1 2.23 0.00E + 00 9.37E − 03 −2.29 4.07E − 03 4.64E − 02
GCM CHUK 2.23 0.00E + 00 9.75E − 03 −1.74 2.25E − 02 2.26E − 01
SMC4L1 2.16 0.00E + 00 1.45E − 02 −2.16 0.00E + 00 6.91E − 02
CENPF 2.14 0.00E + 00 1.60E − 02 −2.02 8.37E − 03 1.05E − 01
CKS1B 2.14 0.00E + 00 1.52E − 02 −1.87 4.00E − 03 1.53E − 01
MORF RFC4 2.09 0.00E + 00 1.77E − 02 −1.82 1.35E − 02 1.70E − 01
PCNA 1.95 1.39E − 02 3.60E − 02 −2.01 8.60E − 03 1.05E − 01
RBBP6 1.93 1.43E − 02 3.65E − 02 −2.20 0.00E + 00 5.82E − 02
TTK 1.89 1.15E − 02 4.36E − 02 −1.95 3.88E − 03 1.27E − 01
MCM4 1.80 1.61E − 02 6.28E − 02 −1.80 1.80E − 02 1.77E − 01
MKI67 1.72 3.09E − 02 8.16E − 02 −1.69 2.56E − 02 2.30E − 01
RFC4 1.71 2.73E − 02 8.55E − 02 −2.08 4.13E − 03 8.40E − 02
CKS2 1.69 2.44E − 02 8.81E − 02 −2.28 0.00E + 00 3.94E − 02
cell division 3.05 0.00E + 00 3.91E − 04 −2.07 5.81E − 03 2.50E − 01
sister chromatid segregation 2.45 0.00E + 00 2.02E − 02 −2.38 0.00E + 00 1.62E − 01
organelle fission 2.29 1.96E − 03 4.17E − 02 −2.11 1.98E − 03 2.17E − 01
nuclear chromosome segregation 2.25 1.97E − 03 4.75E − 02 −2.15 1.96E − 03 1.99E − 01
chromosome segregation 2.23 0.00E + 00 4.63E − 02 −2.52 0.00E + 00 6.91E − 02
macromolecule catabolic process 2.02 2.15E − 03 1.08E − 01 −2.16 3.85E − 03 2.11E − 01
regulation of proteasomal protein catabolic process 1.94 7.95E − 03 1.39E − 01 −2.04 4.12E − 03 2.38E − 01
regulation of proteasomal ubiquitin process 1.76 1.26E − 02 2.33E − 01 −2.30 2.01E − 03 1.84E − 01
transferase complex 2.73 0.00E + 00 1.49E − 03 −2.22 0.00E + 00 2.35E − 01
condensed chromosome centromeric region 2.21 0.00E + 00 3.15E − 02 −2.10 1.99E − 03 1.71E − 01
condensed chromosome 2.16 0.00E + 00 3.17E − 02 −1.90 9.56E − 03 2.45E − 01
catalytic complex 2.03 2.09E − 03 5.35E − 02 −1.97 0.00E + 00 2.45E − 01
nucleoplasm part 1.91 4.29E − 03 8.96E − 02 −1.94 6.24E − 03 2.49E − 01
kinetochore 1.66 3.30E − 02 2.00E − 01 −1.90 7.83E − 03 2.23E − 01
voltage gated cation channel activity −2.37 0.00E + 00 1.30E − 02 2.08 0.00E + 00 1.74E − 01
ERB2 up.v1 dn 3.56 0.00E + 00 0.00E + 00 −3.16 0.00E + 00 0.00E + 00
MEK up.v1 dn 2.30 2.04E − 03 1.74E − 02 −1.65 4.59E − 02 2.25E − 01
EGFR up.v1 dn 1.90 6.01E − 03 6.77E − 02 −1.63 4.11E − 02 2.17E − 01
VEGF a up.v1 dn 1.61 3.01E − 02 1.77E − 01 −1.66 3.09E − 02 2.36E − 01
unstim vs curdlan highdose stim dc up 3.27 0.00E + 00 3.52E − 04 −2.19 0.00E + 00 1.65E − 01
day6 vs day10 traf6ko eff cd8 tcell up 3.02 0.00E + 00 5.32E − 04 −2.90 0.00E + 00 1.12E − 02
day1 vs day7 yf17d vaccine pbmc dn 2.98 0.00E + 00 4.73E − 04 −2.33 0.00E + 00 1.07E − 01
nstim vs mcsf treated monocyte day7 up 2.91 0.00E + 00 5.55E − 04 −2.05 3.87E − 03 2.24E − 01
Continued
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duplication36–38. Furthermore, gene set enrichment analysis demonstrated that CD271+ melanoma cells displayed 
significant correlation with high enrichment scores for the pathways containing E2F motifs and target genes. In 
drastic contrast, CD271+ cells derived from normal melanocytes displayed opposite, negative correlation scores 
with the same transcriptional targets (Fig. 3).
Long-term stem-like maintenance of tumor-initiating subpopulations requires efficient and active DNA repair 
program39. The differential analysis filtered for processes driven by CD271 in tumor-initiating cells revealed 
enrichment for the genes participating in nucleotide excision repair (NER) (Fig. 3C). This molecular pathway is 
of a particular importance to the developing melanomas to compensate for an excessive genomic DNA damage 
induced by ultraviolet (UV) light that may cause replication fork stalling and activation of the cell death machin-
ery40. Activity of the nucleotide excision repair components is therefore critical to remove damaged nucleotides 
that would otherwise prevent effective DNA replication and cell duplication39,40.
Uncontrolled tumor growth is closely connected with a misbalance between cell proliferation and cell death/
differentiation41. In addition to self-renewing factors studied in our systematic analysis of gene expression in 
CD271+ melanoma-initiating cells, a significant upregulation of the major pro-survival network controlled by 
AKT3 was uncovered (Fig. 5). This also included upregulation of SHC2/4, GAB1 and PI3K genes, as well as, other 
critical components of the neurotrophin/CD271 signal transduction network mediating pro-survival program 
(Fig. 5). Interestingly, previous studies in metastatic brain melanomas had shown that CD271 knockdown causes 
decreased expression of AKT3 and predisposes them to the induction of apoptosis24. Moreover, lineage tracing of 
melanoma cancer stem cells exposed to a transient TNF signal showed that these cells expanded and increased in 
stemness in response to the TNF cue and that the PI3K/AKT pathway was necessary for this expansion42. Even 
more intriguing were recent discoveries that TNF produced in an inflammatory response by transfused engi-
neered CD8+ cells in adoptive cell therapy (ACT), induces dedifferentiation and survival of CD271+ melanoma 
cells with concomitant downregulation of targeted markers, resulting in relapse and eventual disease progres-
sion18,19. Importantly, a recent study indicates that CD271 can be used as a guide to target tumor-initiating cells 
Pathway
Melanoma Melanocytes
NES p value q value NES p value q value
ctrl vs anti igm stim bcell 12 h up 2.72 0.00E + 00 2.18E − 03 −2.16 0.00E + 00 1.90E − 01
ctrl vs anti igm stim bcell 2 h up 2.67 0.00E + 00 2.38E − 03 −2.33 0.00E + 00 1.03E − 01
day15 effector vs day30 exhausted cd8 tcell lcmv dn 2.48 0.00E + 00 6.34E − 03 −2.35 2.02E − 03 1.06E − 01
ctrl vs tgfbeta1 il6 il23a cd4 tcell up 2.41 0.00E + 00 8.57E − 03 −2.69 0.00E + 00 3.05E − 02
naive vs day4.5 eff cd8 tcell dn 2.32 0.00E + 00 1.23E − 02 −2.07 0.00E + 00 2.27E − 01
naive vs klrg1high eff cd8 tcell dn 2.29 0.00E + 00 1.37E − 02 −2.27 0.00E + 00 1.33E − 01
n vs fat treg up 2.23 2.02E − 03 1.78E − 02 −2.42 0.00E + 00 9.79E − 02
a2ar ko vs a2ar agonist treated treg dn 2.21 2.11E − 03 1.97E − 02 −2.19 1.97E − 03 1.71E − 01
day6 vs day10 eff cd8 tcell up 2.15 2.03E − 03 2.53E − 02 −3.00 0.00E + 00 7.10E − 03
iver dc vs pln dc activated allogenic tcell dn 2.01 6.05E − 03 4.36E − 02 −2.15 1.93E − 03 1.78E − 01
gfb and il4 vs tgfb and il12 treated act cd4 tcell 6 h dn 2.00 8.11E − 03 4.51E − 02 −2.07 1.96E − 03 2.32E − 01
tconv vs foxp3 ko induced treg dn 1.99 6.07E − 03 4.65E − 02 −2.39 0.00E + 00 1.07E − 01
teff vs tconv day5 in culture up 1.96 1.26E − 02 5.12E − 02 −2.22 0.00E + 00 1.56E − 01
ctrl vs cpg 1 h bmdc up 1.95 8.46E − 03 5.54E − 02 −2.16 0.00E + 00 1.84E − 01
tconv vs treg 24 h tnf stim up 1.89 1.19E − 02 6.61E − 02 −2.53 0.00E + 00 5.21E − 02
nstim vs mcsf treated monocyte day3 up 1.83 1.38E − 02 8.20E − 02 −2.20 2.02E − 03 1.76E − 01
wt vs sap1a ko dp thymocytes up 1.82 1.22E − 02 8.50E − 02 −2.07 5.78E − 03 2.27E − 01
2 h vs 12 h anti igm stim bcell up 1.74 2.69E − 02 1.09E − 01 −2.28 4.12E − 03 1.30E − 01
ctrl vs tgfbeta3 il6 il23a cd4 tcell up 1.74 3.93E − 02 1.10E − 01 −2.37 0.00E + 00 1.10E − 01
spleen c57bl6 vs 4t1 tumor balbc monocytes dn 1.73 2.60E − 02 1.15E − 01 −2.47 0.00E + 00 7.72E − 02
laiv vs tiv flu vaccine day7 pdc up 1.70 3.05E − 02 1.26E − 01 −2.05 5.76E − 03 2.23E − 01
wt vs stat6 ko macrophage dn 1.69 1.90E − 02 1.27E − 01 −2.15 1.88E − 03 1.79E − 01
untreated vs tgfb il6 treated cd4 tcell up 1.65 3.41E − 02 1.47E − 01 −2.58 0.00E + 00 4.25E − 02
wt vs ikaros ko granulocyte monocyte progenitor up 1.64 3.33E − 02 1.50E − 01 −2.30 0.00E + 00 1.17E − 01
STAT5 ab knockin vs wt tcell il2 treated 6 h dn 1.63 2.54E − 02 1.50E − 01 −2.19 0.00E + 00 1.68E − 01
protein secretion 3.01 0.00E + 00 0.00E + 00 2.01 3.88E − 03 3.28E − 02
fatty acid metabolism 1.89 7.69E − 03 4.76E − 02 2.02 0.00E + 00 3.91E − 02
morf AP2m1 2.57 0.00E + 00 3.30E − 03 2.28 0.00E + 00 1.51E − 01
Table 1. Significant overrepresentation of tumor progression associated pathways in CD271+ melanoma-
initiating cells vs CD271− melanoma cells, and vs normal melanocytes. The enrichment study includes 
normalization of the enrichment score accounting for size of each gene set, yielding the normalized enrichment 
score (NES). In addition to the calculated probability during hypothesis testing (p value), there is adjustment for 
multiple hypotheses testing by controlling the proportion of false positives by calculating the false discovery rate 
(q value) corresponding to each NES, and by comparing tails of the observed and the null distribution for the 
NES. Scores are highlighted in bold and italic for positive and negatives NES values, respectively.
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in melanoma patient derived xenografts resulting in significant suppression of metastases to lymph nodes and 
distant organs17. Moreover, CD271 knockdown can abrogate proliferation of cells derived from melanoma as well 
as head and neck cancer patients to significantly reduce their tumor forming capacity in-vivo11,26.
In summary, by contrasting melanoma pathogenesis with normal cellular development in melanocytes, 
CD271 was revealed as a molecular switch. Our data demonstrate that CD271 is associated with activation 
and repression of distinct gene sets, which under pathological conditions control self-renewal and survival, 
as opposed to differentiation and cell death in the normal tissue homeostasis (Figs 1–3). The direction of the 
response in each case was determined by the underlying cellular fate of the specimens. In melanoma, CD271 
governs processes underlying tumor progression, while in a melanocyte environment CD271 accompanies skin 
differentiation processes. By playing a critical role in activating signaling cascades that support melanoma cell 
survival and self-renewing capacity, as well as, their metastases, CD271 unveils itself as a potentially powerful 
therapeutic target for the treatment of metastatic disease. Further development of tumor-specific CD271 blocking 
modalities, including small molecule compounds that inhibit its function and subsequent activation of the down-
stream signal transduction pathways, identified in this report, can provide effective anti-melanoma targeting 
therapy approaches and synergize with immune-modulating agents.
Materials and Methods
Tumor cell isolation. Human tumor specimens were provided by Stanford University Hospital after 
obtaining informed patient consent under the Institutional Review Board Protocol (IRB) approved by Research 
Compliance Office of Stanford Cancer Center. Handling and isolation of human tumor cells from surgical sam-
ples was carried out in accordance with the guidelines and regulations of the approved protocol and previously 
described9. Normal, adult human melanocyte cells were a kind gift by the Dr. Ganesan laboratory, UC Irvine 
(originally purchased from Promocell C-12403). Briefly, tumor tissues were finely minced and incubated in 
Media 199 with added liberase Blendzyme TM mix at the final concentration 60 μg/ml at 37 °C. Tumor cell solu-
tion was filtered through 70 μm nylon mesh and 30 ml of HBSS containing 2 percent heat-inactivated fetal bovine 
serum (FBS) was added to neutralize enzyme activity, which was then centrifuged at 258 × g for 5 min at 5 °C. 
After several washes in HBSS containing 2 percent FBS, cells were centrifuged and resuspended in 500 μl of HBSS 
containing 2 percent FBS and used for the staining protocol described below.
FACS-based purification of CD271+ and CD271− cell populations. Prior to antibody staining, block-
ing reagent, mouse IgG (1 mg/ml) was added to the melanoma or adult melanocyte cell suspension and incubated 
on ice for 10 min. All stainings were performed in 100 μl volume of cold HBSS containing 2 percent FBS. The 
following lineage antibodies were added: CD45, CD31, CD2, CD3, glycophorin A, EpCAM (all conjugated to 
pacific blue) plus an antibody against CD271 (Alexa Fluor647-conjugated) at a 1:50 dilution. Cells were incubated 
on ice in the dark for 30 min. After washing and centrifugation, cells were resuspended in 0.5 ml Hank’s balanced 
salt solution (HBSS) containing 2% FBS and propidium iodide to allow exclusion of nonviable cells. CD271+ and 
Figure 5. Switch in the neurotrophin pathway depends on the expression of the nerve growth factor receptor 
(CD271/NGFR/p75NTR). Gene expression levels plotted onto map of the neurotrophin pathway in CD271+ 
melanoma-initiating cells. Two divergent arms of neurotrophin signaling balance between self-renewing, cell 
survival and cell cycle signals on the one hand, and developmental, differentiation and apoptosis triggers on the 
other hand.
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CD271− cell populations were gated based on the isotype control background signal. Isolation of CD271+ and 
CD271− cells was achieved using a FACSAria III (BD Biosciences, San Jose, CA) cell sorter instrument.
Transcriptome profiling of CD271+ and CD271− cell populations in melanoma and mel-
anocytes. Total RNA was extracted from CD271+ and CD271− cell populations using Trizol Reagent 
(T9424-Millipore-Sigma). All RNA samples were processed using Ovation Pico WTA system V2.0 (NuGEN 
Technologies San Carlos, CA) and hybridized to the Human Genome U133 Plus 2.0 microarray (Affymetrix, 
Santa Clara, CA) chips. Following hybridization and scanning fluorescent signals were obtained for 54675 
probes that were further processed and mapped to 20535 gene-coding transcripts. The RMA oligo package was 
used for normalization and background correction of transcriptomic data. We utilized melanoma and melano-
cyte specimens sorted for CD271 expression status and subjected the data to unsupervised clustering analysis. 
CD271+ and CD271− specimens are denoted as CD271+ and CD271−, respectively. Both, rows (genes) and col-
umns (specimens) were clustered using Pearson correlation distance and average linkage of log-transformed, 
normalized transcriptome array values. Pathway and enrichment analysis was performed by Ingenuity Pathway 
Analysis (IPA) software (QIAGEN Bioinformatics, Germany) and mapped with Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway analysis. The enrichment study includes normalization of the enrichment score 
accounting for size of each gene set, yielding normalized enrichment score (NES). In addition to the calculated 
probability (p value) of hypothesis testing, there is adjustment for multiple hypothesis testing by controlling the 
proportion of false positives by calculating the false discovery rate (q values) corresponding to each NES, by com-
paring tails of the observed and the null distribution for the NES.
Transcriptomic validation by qRT-PCR (quantitative real-time PCR). Total RNA was extracted from 
CD271+ and CD271− melanoma and melanocyte cells using Trizol (T9424-100ML, Millipore-Sigma, Darmstadt, 
Germany). The messenger RNAs of biological triplicates (N = 3) were reverse transcribed into cDNAs using 
Verso cDNA synthesis kits (AB1453A, Life Technologies, Carlsbad, CA), followed by real-time PCR using KAPA 
SYBR® FAST qPCR Master Mix (2X) Kit (Millipore-Sigma, Darmstadt, Germany) and gene-specific primer sets 
(Supplementary Table 2). Values were normalized against 18S RNA using the ΔCT method43,44.
Data Availability
Data is deposited under accession NCBI GEO entry GSE130244.
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